Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |
| rheum:start [2026/03/13 21:22] – Create Rheumatology landing page wilkie | rheum:start [2026/03/13 22:43] (current) – Format rheumatology & immunosuppressants landing page wilkie |
|---|
| ====== Rheumatology ======**Inflammatory & autoimmune disease pharmacology** <WRAP center round box 85%>This section organizes rheumatologic therapy by **immune pathway, drug class, and clinical use**.Start with foundational immunology, then move to drug classes and disease‑specific protocols.</WRAP>----===== Quick Start ===== * **Foundations:** [[basics:start|Immunology Physiology]] · [[allergy:start|Histamine / Hypersensitivity]] · [[eicosanoids:start|Eicosanoids (NSAIDs & Leukotrienes)]] * **Core classes:** [[rheum:dmards:start|Conventional DMARDs]] · [[rheum:biologics:start|Biologic DMARDs]] · [[rheum:jak:start|JAK/Targeted Therapies]] · [[rheum:glucocorticoids:start|Glucocorticoids]] * **Key diseases:** [[rheum:ra:start|Rheumatoid Arthritis]] · [[rheum:psa:start|Psoriatic Arthritis]] · [[rheum:as:start|Ankylosing Spondylitis]] · [[rheum:sle:start|Systemic Lupus (SLE)]] · [[rheum:gout:start|Gout]]----===== Drug Classes ========= Conventional DMARDs ==== * [[rheum:dmards:methotrexate|Methotrexate]] * [[rheum:dmards:hydroxychloroquine|Hydroxychloroquine]] * [[rheum:dmards:sulfasalazine|Sulfasalazine]] * [[rheum:dmards:leflunomide|Leflunomide]]==== Biologic DMARDs ==== * [[rheum:biologics:tnf|TNF inhibitors]] (adalimumab, etanercept, infliximab, etc.) * [[rheum:biologics:il6|IL‑6 inhibitors]] (tocilizumab, sarilumab) * [[rheum:biologics:il17|IL‑17 inhibitors]] (secukinumab, ixekizumab) * [[rheum:biologics:il12_23|IL‑12/23 inhibitors]] (ustekinumab) * [[rheum:biologics:bcell|B‑cell depletion]] (rituximab) * [[rheum:biologics:tcell|T‑cell co‑stimulation]] (abatacept) * [[rheum:biologics:complement|Complement inhibitors]] (eculizumab)==== Targeted Small Molecules ==== * [[rheum:jak:start|JAK inhibitors]] (tofacitinib, baricitinib, upadacitinib) * [[rheum:smallmolecules:pde4|PDE4 inhibitors]] (apremilast) * [[rheum:smallmolecules:other|Other targeted agents]]==== Glucocorticoids ==== * [[rheum:glucocorticoids:start|Systemic steroids]] * [[rheum:glucocorticoids:local|Local / intra‑articular]]----===== Disease‑Specific Pathways ===== * [[rheum:ra:start|Rheumatoid Arthritis (RA)]] * [[rheum:psa:start|Psoriatic Arthritis (PsA)]] * [[rheum:as:start|Ankylosing Spondylitis / AxSpA]] * [[rheum:sle:start|Systemic Lupus Erythematosus (SLE)]] * [[rheum:vasculitis:start|Vasculitides]] * [[rheum:myositis:start|Inflammatory Myopathies]] * [[rheum:giant_cell:start|Giant Cell Arteritis]] * [[rheum:sjogren:start|Sjögren Syndrome]]----===== Monitoring & Safety ===== * [[rheum:monitoring:start|Baseline & ongoing monitoring]] * [[rheum:infection_risk:start|Infection risk & vaccines]] * [[rheum:pregnancy:start|Pregnancy & lactation considerations]] * [[rheum:screening:start|TB / Hep B screening]]----===== Pearls & Tables ===== * [[rheum:pearls:start|Clinical pearls]] * [[rheum:tables:start|Mechanism → adverse effect tables]] * [[rheum:comparisons:start|Head‑to‑head comparisons]] | ====== Rheumatology & Immunosuppressants ======**Inflammatory & autoimmune disease pharmacology** <WRAP center round box 85%>This section organizes therapy by **immune pathway -> drug class -> clinical use**.Start with foundations, then move through drug classes and disease-specific pathways.</WRAP>----===== Quick Start ===== * **Foundations:** [[basics:start|Immunology Physiology]] · [[allergy:start|Histamine / Hypersensitivity]] · [[eicosanoids:start|Eicosanoids (NSAIDs & Leukotrienes)]] * **Core classes:** [[rheum:dmards:start|Conventional DMARDs]] · [[rheum:biologics:start|Biologic DMARDs]] · [[rheum:jak:start|JAK / Targeted Therapies]] · [[rheum:glucocorticoids:start|Glucocorticoids]] * **Key diseases:** [[rheum:ra:start|Rheumatoid Arthritis]] · [[rheum:psa:start|Psoriatic Arthritis]] · [[rheum:as:start|Ankylosing Spondylitis]] · [[rheum:sle:start|Systemic Lupus (SLE)]] · [[rheum:gout:start|Gout]]----===== Drug Classes ========= Conventional DMARDs ==== * [[rheum:dmards:methotrexate|Methotrexate]] * [[rheum:dmards:hydroxychloroquine|Hydroxychloroquine]] * [[rheum:dmards:sulfasalazine|Sulfasalazine]] * [[rheum:dmards:leflunomide|Leflunomide]] * [[rheum:dmards:azathioprine|Azathioprine]] * [[rheum:dmards:mycophenolate|Mycophenolate]]==== Biologic DMARDs ==== * [[rheum:biologics:tnf|TNF inhibitors]] (adalimumab, etanercept, infliximab, etc.) * [[rheum:biologics:il6|IL-6 inhibitors]] (tocilizumab, sarilumab) * [[rheum:biologics:il17|IL-17 inhibitors]] (secukinumab, ixekizumab) * [[rheum:biologics:il12_23|IL-12/23 inhibitors]] (ustekinumab) * [[rheum:biologics:bcell|B-cell depletion]] (rituximab) * [[rheum:biologics:tcell|T-cell co-stimulation]] (abatacept) * [[rheum:biologics:complement|Complement inhibitors]] (eculizumab)==== Targeted Small Molecules ==== * [[rheum:jak:start|JAK inhibitors]] (tofacitinib, baricitinib, upadacitinib) * [[rheum:smallmolecules:pde4|PDE4 inhibitors]] (apremilast) * [[rheum:smallmolecules:other|Other targeted agents]]==== Calcineurin / mTOR ==== * [[rheum:calcineurin:tacrolimus|Tacrolimus]] * [[rheum:calcineurin:cyclosporine|Cyclosporine]] * [[rheum:mtor:sirolimus|Sirolimus / Everolimus]]==== Glucocorticoids ==== * [[rheum:glucocorticoids:start|Systemic steroids]] * [[rheum:glucocorticoids:local|Local / intra-articular]]----===== Disease-Specific Pathways ===== * [[rheum:ra:start|Rheumatoid Arthritis (RA)]] * [[rheum:psa:start|Psoriatic Arthritis (PsA)]] * [[rheum:as:start|Ankylosing Spondylitis / AxSpA]] * [[rheum:sle:start|Systemic Lupus Erythematosus (SLE)]] * [[rheum:vasculitis:start|Vasculitides]] * [[rheum:myositis:start|Inflammatory Myopathies]] * [[rheum:giant_cell:start|Giant Cell Arteritis]] * [[rheum:sjogren:start|Sjogren Syndrome]] * [[rheum:ibd:start|IBD-associated arthritis]]----===== Monitoring & Safety ===== * [[rheum:monitoring:start|Baseline & ongoing monitoring]] * [[rheum:infection_risk:start|Infection risk & vaccines]] * [[rheum:pregnancy:start|Pregnancy & lactation considerations]] * [[rheum:screening:start|TB / Hep B screening]] * [[rheum:malignancy:start|Malignancy risk]] * [[rheum:drug_interactions:start|Drug interactions]]----===== Pearls & Tables ===== * [[rheum:pearls:start|Clinical pearls]] * [[rheum:tables:start|Mechanism -> adverse effect tables]] * [[rheum:comparisons:start|Head-to-head comparisons]] |
